Medifast (MED) Gets a Buy Rating from Jefferies

Jefferies analyst Stephanie Wissink maintained a Buy rating on Medifast (MEDResearch Report) today and set a price target of $345.00. The company’s shares closed last Tuesday at $179.17.

According to, Wissink is a 1-star analyst with an average return of -2.2% and a 41.6% success rate. Wissink covers the Consumer Goods sector, focusing on stocks such as Petco Health and Wellness Company, Bj’s Wholesale Club Holdings, and The Estée Lauder Companies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medifast with a $348.50 average price target.

See the top stocks recommended by analysts >>

Medifast’s market cap is currently $2.06B and has a P/E ratio of 12.78.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Medifast, Inc. is a health and wellness company, which engages in the manufacture and distribution of healthy living products and programs. Its product lines include weight loss, weight management and healthy living meal replacements, snacks, hydration products, and vitamins. The company was founded by William Vitale in 1980 and is headquartered in Baltimore, MD.

Read More on MED:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More